Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
X. Xie, J. Zou, C. R. Fontes-Garfias, H. Xia, K. A. Swanson, M. Cutler, D. Cooper, V. D. Menachery, S. D. Weaver, P. R. Dormitzer, P.-Y. Shi
Abstract
Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N501 and Y501 viruses.
02 /Specification & Classification
Click any tag to browse matching papers- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Neutralization of spike 69/70 deletion, E484K, and N501Y SARS-CoV-2 by BNT162b2 vaccine-elicited sera
- The basis of a more contagious 501Y.V1 variant of SARS-COV-2
G. Zhang, H. Liu, … P. Marrack·bioRxiv·Feb 2, 2021
- Relative Mutant N501Y SARS-CoV-2 Spike Protein RBD Inhibition of Anti-Spike Protein IgG and ACE-2 Binding to Spike Protein Species
M. E. Klegerman, J. D. Cirillo, D. D. McPherson·bioRxiv·Apr 26, 2021
- Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines
- SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
T. Moyo-Gwete, M. Madzivhandila, … P. Moore·bioRxiv·Mar 6, 2021
- Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies
T. Tada, B. M. Dcosta, … N. R. Landau·bioRxiv·Feb 5, 2021